All In Biotech

Drug Trial Radar · NCT04048135

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100 Administered Subcutaneously in Subjects With Nonalcoholic Steatohepatitis (NASH) or With Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jul 29, 2019

Primary completion

Aug 28, 2020

Study completion Jan 19, 2022

Sponsor

Lead sponsor
89bio, Inc.Industry
Sponsor type
Industry
Collaborators
ProSciento, Inc.
First posted
Aug 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high risk of NASH, including a pre-defined number of participants with biopsy confirmed NASH and fibrosis stages F1-F3 to be enrolled. Part 2: This is a multi-center, open label evaluation of pegozafermin at 27 mg administered weekly for 20 weeks in participants with biopsy-proven NASH (NAS ≥4, fibrosis stage F2 or F3).

Conditions

  • NASH

Interventions

  • PegozaferminDrug

    Subcutaneous injection

  • PlaceboOther

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)Time frame: Up to 113 days
  2. Part 2: Number of Participants With TEAEsTime frame: Up to 162 days
  3. Part 1: Maximum Observed Serum Concentration (Cmax) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
  4. Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
  5. Part 1: Time to Peak Serum Concentration (Tmax) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
  6. Part 1: Terminal Elimination Half-life (t1/2) of PegozaferminTime frame: Predose and up to 168 hours postdose on Day 29
  7. Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of FibrosisTime frame: Day 141

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • 89bio Clinical Study Site

    Madison, Alabama

  • 89bio Clinical Study Site

    Chandler, Arizona

  • 89bio Clinical Study Site

    Tucson, Arizona

  • 89bio Clinical Study Site

    Chula Vista, California

  • 89bio Clinical Study Site

    Huntington Beach, California

  • 89bio Clinical Study Site

    Montclair, California

  • 89bio Clinical Study Site

    Miami, Florida

  • 89bio Clinical Study Site

    Miami Lakes, Florida

  • 89bio Clinical Study Site

    Ocala, Florida

  • 89bio Clinical Study Site

    Sarasota, Florida

  • 89bio Clinical Study Site

    Lake Charles, Louisiana

  • 89bio Clinical Study Site

    Berlin, New Jersey

  • 89bio Clinical Study Site

    Florham Park, New Jersey

  • 89bio Clinical Study Site

    East Syracuse, New York

  • 89bio Clinical Study Site

    Concord, North Carolina

  • 89bio Clinical Study Site

    Raleigh, North Carolina

  • 89bio Clinical Study Site

    Greenwood, South Carolina

  • 89bio Clinical Study Site

    Summerville, South Carolina

  • 89bio Clinical Study Site

    Hermitage, Tennessee

  • 89bio Clinical Study Site

    Austin, Texas

  • 89bio Clinical Study Site

    Edinburg, Texas

  • 89bio Clinical Study Site

    Houston, Texas

  • 89bio Clinical Study Site

    San Antonio, Texas

  • 89bio Clinical Study Site

    San Antonio, Texas

  • 89bio Clinical Study Site

    Wichita Falls, Texas

  • 89bio Clinical Study Site

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.